title: Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
abstract: BACKGROUND
  Esophageal squamous cell carcinoma (ESCC) is often synchronously accompanied by pharyngeal squamous cell carcinoma (PSCC). However, treatment strategies for these synchronous cancers have not been established.
  
  
  OBJECTIVE
  To evaluate retrospectively the effects of both chemoradiotherapy (CRT) targeted for invasive ESCC on synchronous superficial PSCC and additional endoscopic resection (ER) for PSCC.
  
  
  METHODS
  Screening endoscopy in the pharynx was performed in newly diagnosed ESCC patients. CRT combined with 5-fluorouracil (5-FU) and cisplatin (CDDP) was administered to all patients. The effect on superficial PSCC was only evaluated for 5-FU-CDDP chemotherapy that excluded the pharynx from the radiation field. When PSCC was remnant or recurrent in patients evaluated at complete response (CR) of ESCC, ER was performed on the PSCC.
  
  
  RESULTS
  Fourteen cases of superficial PSCC (4.0%) were detected in 348 ESCC patients. Three PSCC reached CR in 8 ESCC-CR patients, while all 3 lesions recurred. No treatment response was found in the remaining 11 PSCC. As a second treatment, ER for 8 PSCC was completed in the 8 ESCC-CR patients, with one complication due to pneumonia.
  
  
  CONCLUSIONS
  Standard 5-FU-CDDP CRT targeted for invasive ESCC did not demonstrate a sufficient efficacy for superficial PSCC, while ER even for PSCC after chemotherapy was curative.
authors.affiliation: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. kkaneko@east.ncc.go.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kaneko
authors.forename: Tomonori
authors.initials: T
authors.lastname: Yano
authors.forename: Keiko
authors.initials: K
authors.lastname: Minashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Kojima
authors.forename: Miki
authors.initials: M
authors.lastname: Ito
authors.forename: Hironaga
authors.initials: H
authors.lastname: Satake
authors.forename: Yoko
authors.initials: Y
authors.lastname: Yajima
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Yoda
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ikematsu
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Oono
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Hayashi
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Onozawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ohtsu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010610:Pharyngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011183:Postoperative Complications; D011379:Prognosis; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D002945:Cisplatin; D005472:Fluorouracil